NCT02981524View on ClinicalTrials.gov

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

March 20, 2018

Study Completion Date

March 20, 2018

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

CY

CY is administered intravenously at 200 mg/m2

BIOLOGICAL

GVAX

GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting

DRUG

Pembrolizumab

Pembrolizumab is administered intravenously at 200 mg

Trial Locations (1)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02981524 - Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter